Lizhen Chen

Dr. Lizhen Chen

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2020 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MBMingjun Bi
Mingjun Bi
ZZZhao Zhang
Zhao Zhang
YJYi-Zhou Jiang
Yi-Zhou Jiang
PXPengya Xue
Pengya Xue
HWHu Wang
Hu Wang
ZLZhijie Liu
Zhijie Liu

1 August 2019 in Molecular Cell
Verified
Journal Article
Closed access
CZChi Zhu
Chi Zhu
LLLi Li
Li Li
ZZZhao Zhang
Zhao Zhang
MBMingjun Bi
Mingjun Bi
HWHu Wang
Hu Wang
ZLZhijie Liu
Zhijie Liu

21 September 2023 in Molecular Cell
Verified
Journal Article
Closed access
LCLizhen Chen
Lizhen Chen
ZZZhao Zhang
Zhao Zhang
QHQinyu Han
Qinyu Han
BMBarun K. Maity
Barun K. Maity
LRLeticia Rodrigues
Leticia Rodrigues
ZLZhijie Liu
Zhijie Liu

13 January 2020 in Autophagy
Verified
Journal Article
Closed access
Su Hyuk KoSu Hyuk Ko
Su Hyuk Ko
EAEllen C. Apple
Ellen C. Apple
ZLZhijie Liu
Zhijie Liu
LCLizhen Chen
Lizhen Chen
Macroautophagy/autophagy is essential for maintaining cellular homeostasis through the degradation of organelles and proteins. It also has a prominent role in modulating aging. However, the role of autophagy in the neuronal response to axon injury and axon regeneration, particularly in the context of aging, remains largely unknown. Our candidate genetic screen for axon regeneration regulators has identified genes in the autophagy pathway. Using a reporter that monitors autophagosomes and autolysosomes, we were able to monitor the dynamics of autophagy during axon regeneration. In response to axon injury, there was a significant increase in the number of autophagic vesicles. Injury-triggered autophagy activation and axon regeneration capacity undergo an age-dependent decline, and autophagy-activating agents partially rescued these declines. We found that DLK-1 was both required and sufficient for injury-induced autophagy activation. Autophagic vesicles co-localized with the NOTCH4 ortholog, LIN-12 receptor, a previously identified inhibitor of axon regeneration. Epistasis analyses indicate that LIN-12 might be a target of autophagy in axon regeneration. Together, our data suggest that DLK-mediated injury signaling can activate autophagy, which might limit the level of LIN-12 and NOTCH proteins to promote axon regeneration. Our findings reveal that autophagy activation can promote axon regeneration in neurons that lack maximal regrowth capacity, providing a promising therapeutic strategy for axon injury.

2 June 2016 in eLife
Verified
Journal Article
Open access
LCLizhen Chen
Lizhen Chen
ZLZhijie Liu
Zhijie Liu
BZBing Zhou
Bing Zhou
CWChaoliang Wei
Chaoliang Wei
Yu ZhouYu Zhou
Yu Zhou
YJYishi Jin
Yishi Jin
Axon injury triggers dramatic changes in gene expression. While transcriptional regulation of injury-induced gene expression is widely studied, less is known about the roles of RNA binding proteins (RBPs) in post-transcriptional regulation during axon regeneration. In C. elegans the CELF (CUGBP and Etr-3 Like Factor) family RBP UNC-75 is required for axon regeneration. Using crosslinking immunoprecipitation coupled with deep sequencing (CLIP-seq) we identify a set of genes involved in synaptic transmission as mRNA targets of UNC-75. In particular, we show that UNC-75 regulates alternative splicing of two mRNA isoforms of the SNARE Syntaxin/unc-64. In C. elegans mutants lacking unc-75 or its targets, regenerating axons form growth cones, yet are deficient in extension. Extending these findings to mammalian axon regeneration, we show that mouse Celf2 expression is upregulated after peripheral nerve injury and that Celf2 mutant mice are defective in axon regeneration. Further, mRNAs for several Syntaxins show CELF2 dependent regulation. Our data delineate a post-transcriptional regulatory pathway with a conserved role in regenerative axon extension.

20 September 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
EZEmily Zboril
Emily Zboril
HYHannah Yoo
Hannah Yoo
LCLizhen Chen
Lizhen Chen
ZLZhijie Liu
Zhijie Liu
While improved tumor treatment has significantly reduced the overall mortality rates, invasive progression including recurrence, therapy resistance and metastasis contributes to the majority of deaths caused by cancer. Enhancers are essential distal DNA regulatory elements that control temporal- or spatial-specific gene expression patterns during development and other biological processes. Genome-wide sequencing has revealed frequent alterations of enhancers in cancers and reprogramming of distal enhancers has emerged as one of the important features for tumors. In this review, we will discuss tumor progression-associated enhancer dynamics, its transcription factor (TF) drivers and how enhancer reprogramming modulates gene expression during cancer invasive progression. Additionally, we will explore recent advancements in contemporary technology including single-cell sequencing, spatial transcriptomics and CUT&RUN, which have permitted integrated studies of enhancer reprogrammingin vivo. Given the essential roles of enhancer dynamics and its drivers in controlling cancer progression and treatment outcome, understanding these changes will be paramount in mitigating invasive events and discovering novel therapeutic targets.